

A biopharmaceutical company developing monoclonal antibody products through use of a proprietary human antibody technology

Morphotek Overview

- **Antibody-focused biopharmaceutical company**



- § founded in 2000, based on a genome evolution technology called *morphogenics*
- § developing fully human antibodies through unique process patents
- § applying validated technology to internal pipeline and partnerships

- **Company focus and value creation**

- § clinical validation of therapeutic antibody pipeline
- § leveraging antibody technology in development partnerships with leading research institutes studying cancer, inflammation and infectious diseases

- **Strong scientific and clinical expertise in biologics and oncology**



- § 2 clinical-stage compounds (MORAb-003 and MORAb-009)
- § multiple preclinical compounds positioned for new Investigational New Drugs (IND)

- **Strong IP position on technology and products**

- § 8 issued patents, >50 under active prosecution
- § significant barrier to entry - many patents extend past 2020

Proprietary Antibody Technology



**Diagnostic reagents
&
Therapeutic leads**



MORPHODOMA[®] Technology

MORPHODOMA[®] Derived Products

Robust pipeline...

Antibody	1 st Indication	Other indications	Description	Collaborator	Stage
MORAb-003	Ovarian cancer	Breast, CRC, NSCLC, Renal	antigen on >90% ovarian tumors	Memorial Sloan Kettering	PH1/PH2
MORAb-009	Pancreatic & lung cancer	CRC, Ovarian	antigen on 100% pancreatic tumors	Johns Hopkins/NCI	PH1
MORAb-004	Neovascular disease	Cancer, ADM, DR	antigen on 100% tumor endothelia	Johns Hopkins/John Wayne	PC
MORAb-022	Rheumatoid arthritis	Asthma, MS, Psoriasis	cytokine involved in RA in mouse models	Ludwig	PC
MORAb-028	Metastatic melanoma	Brain, SCLC	Human mAb with clinical activity melanoma	John Wayne Cancer Institute	PC
MORAb-047	Infectious disease	Biodefense	Antigen produced by pathogenic microbes	USAMRIID	PC
MORAb-048	Infectious disease	Biodefense	Antigen produced by pathogenic microbes	USAMRIID	PC

